<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042066</url>
  </required_header>
  <id_info>
    <org_study_id>RHT-01</org_study_id>
    <secondary_id>0449-13</secondary_id>
    <nct_id>NCT02042066</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension</brief_title>
  <acronym>RHT</acronym>
  <official_title>Efficacy and Safety of Low Intensity- Extracorporeal Shockwave Therapy in Drug Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medispec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medispec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low intensity shockwaves have been proven in animal and human studies to increase tissue
      perfusion, promote angiogenesis and tissue regeneration and improve neural function.

      The hypothesis of this study is that shockwave therapy could improve the symptoms of patients
      with resistant hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in 24 hour ambulatory blood pressure (ABPM) from baseline to six months post last treatment (± 2 weeks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in 24 hour ambulatory blood pressure (ABPM) from baseline to three months post last treatment (± 2 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office Blood Pressure</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in office blood pressure from baseline to three months and six months post last treatment (± 2 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urea and Creatinine</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in serum urea and creatinine from baseline to 3 months and 6 months (± 2 weeks) post last treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in ultrasound-measured renal resistive index (RRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urea and Creatinine</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in serum urea and creatinine from baseline to 3 months and 6 months (± 2 weeks) post last treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office Blood Pressure</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in office blood pressure from baseline to three months and six months post last treatment (± 2 weeks).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypertension, Resistant to Conventional Therapy</condition>
  <arm_group>
    <arm_group_label>Treated Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive actual shockwave treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Omnispec model Vascuspec</intervention_name>
    <description>Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy</description>
    <arm_group_label>Treated Group</arm_group_label>
    <other_name>Vascuspec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have provided written informed consent.

          -  Age ≥18 and ≤80 years old.

          -  Office systolic blood pressure that remains ≥160 mmHg (≥150 mmHg for patient with type
             2 diabetes) despite the stable use of ≥3 antihypertensive medications concurrently at
             maximally tolerated doses, of which one is a diuretic (unless there is a tolerance or
             a contraindication for a diuretics).

          -  Able and willing to comply with the required follow-up schedule.

        Exclusion Criteria:

          -  Subjects who have participated in a clinical study involving another investigational
             drug or device within 4 weeks prior to Screening.

          -  Have hypertension secondary to an identifiable and treatable cause or take medication
             that can raise the BP.

          -  Prior renal artery intervention (balloon angioplasty or stenting).

          -  Pregnancy.

          -  Uncompensated heart failure.

          -  Chronic Liver Disease.

          -  Patients with skin wound / infection at the treatment area.

          -  Subjects who take oral anti-coagulants.

          -  Local tumor of treatment area.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayelet Shauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayelet Shauer, MD</last_name>
    <phone>+972-2-6776564</phone>
    <email>aye.shauer@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayelet Shauer, MD</last_name>
      <phone>+972-2-6776564</phone>
      <email>aye.shauer@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ayelet Shauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Libovitz, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ido Ben-Dov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shmuel Hen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Orlev, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resistant Hypertension</keyword>
  <keyword>RH</keyword>
  <keyword>RHT</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Kidney</keyword>
  <keyword>Shockwave</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Coronary Vasospasm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

